Tags

Type your tag names separated by a space and hit enter

Investigation of Betaserc in auditory and vestibular disturbances.
Int Tinnitus J. 2004; 10(2):177-82.IT

Abstract

Vestibular vertigo is a primary symptom in neurootological clinical practice and is common among cerebrovascular diseases. The aim of this investigation was to evaluate the effect of betahistine dihydrochloride (Betaserc), 8 and 16 mg, on patients who were transport system workers with vascular auditory and vestibular disturbances. We examined 50 patients, 30 of whom were treated with 16-mg doses and 20 of whom received 8-mg doses of Betaserc. The mean age of the patients was 37+/-2.3 years. The following evaluative methods were used: questionnaire including detailed neurootological history; ear, nose, and throat and neurological examinations; tonal threshold audiometry; and examination of the vestibular system (spontaneous and provoked reactions). On the basis of the investigations carried out, we recommend 16 mg Betaserc three times daily in the acute phase. The medication is very well tolerated, has no sedative effect and is suitable for long-term treatment.

Authors+Show Affiliations

Department of Neurology and Neurootology, National Transport Hospital, Tzar Boris III, Sofia, Bulgaria. drpetrova@abv.bgNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15732519

Citation

Petrova, Dorina, et al. "Investigation of Betaserc in Auditory and Vestibular Disturbances." The International Tinnitus Journal, vol. 10, no. 2, 2004, pp. 177-82.
Petrova D, Sachansca T, Datcov E. Investigation of Betaserc in auditory and vestibular disturbances. Int Tinnitus J. 2004;10(2):177-82.
Petrova, D., Sachansca, T., & Datcov, E. (2004). Investigation of Betaserc in auditory and vestibular disturbances. The International Tinnitus Journal, 10(2), 177-82.
Petrova D, Sachansca T, Datcov E. Investigation of Betaserc in Auditory and Vestibular Disturbances. Int Tinnitus J. 2004;10(2):177-82. PubMed PMID: 15732519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Investigation of Betaserc in auditory and vestibular disturbances. AU - Petrova,Dorina, AU - Sachansca,Teodora, AU - Datcov,Emil, PY - 2005/3/1/pubmed PY - 2005/10/15/medline PY - 2005/3/1/entrez SP - 177 EP - 82 JF - The international tinnitus journal JO - Int Tinnitus J VL - 10 IS - 2 N2 - Vestibular vertigo is a primary symptom in neurootological clinical practice and is common among cerebrovascular diseases. The aim of this investigation was to evaluate the effect of betahistine dihydrochloride (Betaserc), 8 and 16 mg, on patients who were transport system workers with vascular auditory and vestibular disturbances. We examined 50 patients, 30 of whom were treated with 16-mg doses and 20 of whom received 8-mg doses of Betaserc. The mean age of the patients was 37+/-2.3 years. The following evaluative methods were used: questionnaire including detailed neurootological history; ear, nose, and throat and neurological examinations; tonal threshold audiometry; and examination of the vestibular system (spontaneous and provoked reactions). On the basis of the investigations carried out, we recommend 16 mg Betaserc three times daily in the acute phase. The medication is very well tolerated, has no sedative effect and is suitable for long-term treatment. SN - 0946-5448 UR - https://www.unboundmedicine.com/medline/citation/15732519/Investigation_of_Betaserc_in_auditory_and_vestibular_disturbances_ L2 - https://medlineplus.gov/dizzinessandvertigo.html DB - PRIME DP - Unbound Medicine ER -